Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease-Reference-Cited by-同舟云学术

Phosphodiesterase Type 5 Inhibitors and Oral Nitrates in Male Patients with Ischemic Heart Disease

Published:2023-04-19 Issue:6 Volume:25 Page:553-560
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Morrisette Matthew J.,Dunn Steven P.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11886-023-01873-y.pdf

Reference27 articles.

1. About Multiple Cause of Death, 1999–2000 [Internet]. Ctr Dis Control Prev. 2022 [cited 2022 Feb 21]. Available from: https://wonder.cdc.gov/mcd-icd10.html.

2. Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006;27:2640–8.

3. Chrysant SG, Chrysant GS. The pleiotropic effects of phosphodiesterase 5 inhibitors on function and safety in patients with cardiovascular disease and hypertension. J Clin Hypertens (Greenwich). 2012;14:644–9.

4. Dahabreh IJ, Paulus JK. Association of episodic physical and sexual activity with triggering of acute cardiac events: systematic review and meta-analysis. JAMA. 2011;305:1225–33.

5. Chang L-L, Ma M, von Allmen H, Henderson SC, Harper K, Hornbuckle K. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates. Curr Med Res Opin. 2010;26:1451–9.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Counterfeiting honey with phosphodiesterase inhibitors for sexual activity enhancement: detection using high-performance liquid chromatography coupled with a photodiode array detector (HPLC-PAD);Journal of Men's Health;2024

2. Authors’ Reply to Ganijee et al.: “Comment on: Evaluation of the Influence of Sildenafil on Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Vericiguat in Healthy Adults”;Clinical Pharmacokinetics;2023-09-26